IHE Falls 1.91% and RSPH 2.56% in a Health Care Slide

The iShares U.S. Pharmaceuticals ETF (IHE) fell 1.91% to 102.68 and the Invesco S&P 500 Equal Weight Health Care ETF (RSPH) fell 2.56% to 36.49 as of the last trade at 20:00 GMT on Sept. 8, 2026, both trailing the S&P 500's 0.55% decline.

Two exchange-traded funds that both put the word "health" in the pitch behaved differently on Tuesday, and the gap between them is a useful window into what an investor is actually buying when they choose one over the other.

The iShares U.S. Pharmaceuticals ETF (IHE) was quoted at 102.68 as of the last trade at 20:00 GMT on Sept. 8, 2026, down 1.91% from a previous close of 104.68. It traded between 102.16 and 103.22 on the session, finishing near the low. The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) was quoted at 36.49, down 2.56% from 37.45, with a day range of 36.49 to 37.01 — it also ended at the bottom of its band.

Both funds lagged the broad market. The S&P 500, via SPY, was down 0.55% at $765.96. The Nasdaq 100 (QQQ) was close to flat at $718.36, off 0.08%, while the Dow 30 (DIA) fell 1.13% to $528.03. On the day, IHE underperformed the S&P 500 by roughly 1.36 percentage points and RSPH by about 2.01 percentage points, using those quoted moves.

Concentration versus spread: what each fund is designed to do

The structural difference is the whole story. As Nasdaq Markets frames it, IHE provides concentrated exposure to the pharmaceutical industry, while RSPH offers broad health care exposure using an equal-weight approach.

Concentrated means the fund lives or dies on one slice of the sector: branded and generic drugmakers, their pipelines, their patent cliffs, their pricing politics. It does not spread the risk across hospital operators, insurers, device makers, distributors or life-science tools companies. When drug pricing headlines land or a large-cap pharma name reports a trial result, a concentrated pharma fund moves with it.

Equal weight means the opposite instinct. Rather than sizing each holding by market capitalisation — which lets the largest three or four companies dominate returns — an equal-weight sector fund gives every constituent of the S&P 500 health care sector a similar slice, and rebalances periodically back toward parity. The effect is to tilt the fund away from the megacaps and toward the mid-sized names in the index. That tilt is a genuine bet, not a neutral choice: it pays off when the sector's smaller members outrun its giants and drags when leadership is narrow.

Tuesday's split points to where the pain was

On this single session, the equal-weight fund fell harder. RSPH's 2.56% decline was 0.65 percentage points steeper than IHE's 1.91% drop, based on the quoted moves. One day proves nothing about long-run performance, but the direction is consistent with a market punishing the broader, more cyclical parts of health care — the service, device and payer businesses that sit outside a pure pharma basket — more than the drugmakers themselves.

It is also worth noting the context. The Dow's 1.13% fall was the weakest of the three benchmarks quoted, while the tech-heavy Nasdaq 100 was essentially unchanged. That pattern — old-economy and defensive names down, large-cap technology flat — is not a health-care-specific event. Both ETFs were caught in it, and both were caught worse than the index.

The cost and holdings questions an investor still has to answer

Price action tells you what happened; it does not tell you what to own. Three variables decide the comparison over a holding period measured in years rather than hours.

• Expense ratio. Industry-specific and equal-weight products generally carry higher fees than plain-vanilla cap-weighted index funds, because they involve narrower baskets and, in the equal-weight case, regular rebalancing. Check the current prospectus figures for both before assuming the cheaper-looking option is cheaper.
• Concentration risk. A pharma-only fund's top holdings can account for a large share of assets. That is the point of the product — but it means a single company's litigation, approval or pricing setback can dominate the fund's return.
• Rebalancing drag and turnover. Equal-weight funds trade more than cap-weighted ones by construction. In a taxable account, that matters.

There is also a definitional trap. "Health care" as an S&P 500 sector is a far wider church than "pharmaceuticals." An investor who buys RSPH thinking they have bought drug innovation has in fact bought a diversified basket in which drugmakers are one component among several. An investor who buys IHE thinking they have bought defensive health care has in fact bought a single industry with distinctive political and patent-cycle risk.

What determines which one wins from here

The honest answer is that the two funds are not substitutes and the comparison depends on the view being expressed.

If the thesis is that drug pricing pressure has peaked and pipelines are set to deliver, the concentrated fund is the sharper instrument. It has less to dilute the payoff. If the thesis is that health care as a whole is undervalued relative to the market but the megacaps within it are crowded, the equal-weight structure is the closer fit — it deliberately reduces the weight of the biggest names and raises the weight of everything else.

Investors should watch three things over the coming quarters. First, whether sector leadership is narrow or broad: narrow leadership favours cap-weighted and concentrated products, broad participation favours equal weight. Second, the policy calendar, since drug pricing decisions hit IHE's constituents directly and RSPH's only partially. Third, the funds' actual total returns — price plus distributions — over one, three and five years, which is the only apples-to-apples measure and the one a single day's quote cannot supply.

For now the tape says the concentrated pharma basket held up marginally better than the diversified equal-weight one, and that both were weaker than the S&P 500 on the day. Those are facts about Sept. 8, 2026, not a verdict on either strategy.

Key facts

• IHE last trade: 102.68, -1.91% (as of 20:00 GMT, Sept. 8, 2026)
• RSPH last trade: 36.49, -2.56% (as of 20:00 GMT, Sept. 8, 2026)
• S&P 500 (SPY): $765.96, -0.55% on the day
• Structural difference: IHE is concentrated pharma; RSPH is equal-weight S&P 500 health care

Frequently asked questions

How did IHE and RSPH perform on Sept. 8, 2026?

The iShares U.S. Pharmaceuticals ETF (IHE) was quoted at 102.68, down 1.91% from a previous close of 104.68, with a day range of 102.16 to 103.22. The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) was quoted at 36.49, down 2.56% from 37.45, with a range of 36.49 to 37.01, both as of 20:00 GMT.

What is the difference between the two funds?

IHE provides concentrated exposure to the pharmaceutical industry, meaning its holdings are drugmakers. RSPH offers broad health care exposure across the S&P 500 health care sector using an equal-weight approach, which gives each constituent a similar allocation rather than sizing them by market capitalisation. They are not substitutes for one another.

What does equal weight actually mean?

An equal-weight fund allocates roughly the same amount to every company in its index rather than weighting by market value. It rebalances periodically back toward parity, which reduces the influence of the largest companies and increases the influence of mid-sized ones. The trade-off is higher turnover and a deliberate tilt away from megacap leadership.

Did both ETFs underperform the market that day?

Yes. The S&P 500, tracked by SPY, fell 0.55% to $765.96. IHE fell 1.91% and RSPH fell 2.56%, so both trailed the broad index. The Dow 30 (DIA) was down 1.13% at $528.03 while the Nasdaq 100 (QQQ) was nearly flat at $718.36, off 0.08%.

Which fund carries more single-company risk?

The concentrated pharma fund, by design. Because IHE holds only pharmaceutical companies, a large individual holding's litigation outcome, regulatory decision or patent expiry can move the whole fund. RSPH spreads risk across the wider health care sector and, through equal weighting, limits how much any one constituent can dominate returns.

What should investors check before choosing between them?

Current expense ratios from each fund's prospectus, the concentration of the top holdings, portfolio turnover and its tax consequences in a taxable account, and total returns including distributions over one, three and five years. A single session's price move, however sharp, says little about long-run relative performance.

Sources

• Does iShares Pharma ETF Offer Superior Returns to Invesco's Equal Weight Healthcare Fund? — Nasdaq Markets

Photo: Yaroslav Shuraev · Pexels Licence — source